Evidence map›Paper›PMID 30989732›Full record

ArticleMolecular carcinogenesis2019

Potentially functional genetic variants in the TNF/TNFR signaling pathway genes predict survival of patients with non-small cell lung cancer in the PLCO cancer screening trial.

Yi Guo, Yun Feng, Hongliang Liu, Sheng Luo, Jeffrey W Clarke, Patricia G Moorman, Li Su, Sipeng Shen, David C Christiani, Qingyi Wei

Open access · greenAbstract read
In one paragraph

Article in Molecular carcinogenesis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Genetic Variants ofFrontiers in oncology · 2021
    Article
  10. Anti-Colorectal Cancer Mechanisms of Formononetin Identified by Network Pharmacological Approach.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Yi GuoDepartment of Pulmonary and Critical Care Medicine, Shanghai Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yun FengDepartment of Pulmonary and Critical Care Medicine, Shanghai Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Hongliang LiuDepartment of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.
Sheng LuoDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
Jeffrey W ClarkeDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Patricia G MoormanDepartment of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.
Li SuDepartments of Environmental Health and Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Sipeng ShenDepartments of Environmental Health and Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
David C ChristianiDepartments of Environmental Health and Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Qingyi WeiDepartment of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0002-5265-3930
Duke University · USMassachusetts General Hospital · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
JH/CIDR Genotyping for Genome-Wide Association StudiesU01HG004438 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 2007 to 2011
$24.2M
The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2M
Translational studies of Hsp90 inhibitors in NSCLCP50CA090578 · NCI · DANA-FARBER CANCER INST · PI YEAP, BEOW Y · 2008 to 2012
$11.4M
Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
Genome Wide Association Coordinating CenterU01HG004446 · NHGRI · UNIVERSITY OF WASHINGTON · PI WEIR, BRUCE S. · 2007 to 2011
$6.6M
Molecular and Genetic Analysis of Lung Cancer SurvivalR01CA092824 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI CHRISTIANI, DAVID C · 2002 to 2013
$5.9M
SPORE in Lung CancerP20CA090578 · NCI · DANA-FARBER CANCER INSTITUTE · PI JOHNSON, BRUCE E. · 2003 to 2007
$5.1M
GENETIC SUSCEPTIBILITY TO LUNG CANCERR01CA074386 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI CHRISTIANI, DAVID C · 1997 to 2008
$4.8M
Statistical Methods for Clinical Trials with Multivariate Longitudinal OutcomesR01NS091307 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LUO, SHENG · 2015 to 2018
$1.2M
Genome-Wide Association StudiesZ01CP010200 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI FRAUMENI, JOSEPH · 2008 to 2008
$50k
Intramural NIH HHS Z01 CP010200NCI NIH HHS P20 CA090578NCI NIH HHS P30 CA014236NCI NIH HHS P50 CA090578NCI NIH HHS R01 CA074386NCI NIH HHS R01 CA092824NCI NIH HHS R35 CA197449NCI NIH HHS U01 CA209414NHGRI NIH HHS U01 HG004438NHGRI NIH HHS U01 HG004446NINDS NIH HHS R01 NS091307
6 · The paper itself

Abstract

The tumor necrosis factor (TNF)/TNF receptor (TNFR) pathway is known to influence survival of patients with cancer. We hypothesize that single nucleotide polymorphisms (SNPs) in the TNF/TNFR pathway genes related to apoptosis are associated with survival of patients with non-small cell lung cancer (NSCLC). We used 1185 patients with NSCLC in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial and 984 patients with NSCLC in the Harvard Lung Cancer Susceptibility Study as the discovery and validation datasets, respectively. We selected 6788 SNPs in 71 genes in the TNF/TNFR signaling pathway and extracted their genotyping data from the PLCO genowide-association study (GWAS) dataset. We performed Cox proportional hazards regression analysis to evaluate associations between the identified SNPs and survival and validated the significant SNPs, which were further analyzed for their functional relevance. We found that genotypes of two validated SNPs, IKBKAP rs4978754 CT + TT and TNFRSF1B rs677844 TC + CC, as well as their combined genotypes predicted a better overall survival (P = 0.004, 0.002 and <0.001, respectively). These two validated SNPs were predicted by the RegulomeDB score to be potentially functional. In addition, IKBKAP mRNA expression levels were significantly higher, while TNFRSF1B mRNA expression levels were significantly lower in lung cancer tissues than in adjacent normal tissues (P < 0.001). The Cancer Genome Atlas (TCGA)-based expression quantitative trait loci analysis showed that IKBKAP rs4978754 and TNFRSF1B rs677844 genotypes were significantly associated with their corresponding mRNA expression levels in lung cancer tissues in a recessive model (P = 0.035 and 0.045, respectively). Therefore, we identified two potentially functional SNPs (IKBKAP rs4978754 C > T and TNFRSF1B rs677844 T > C) to be associated with survival of patients with NSCLC.

Indexed as

ApoptosisCarcinoma, Non-Small-Cell LungCarrier ProteinsGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansLung NeoplasmsPolymorphism, Single NucleotideQuantitative Trait LociReceptors, Tumor Necrosis Factor, Type IISignal TransductionTranscriptional Elongation FactorsTumor Necrosis Factor-alphaCarrier ProteinsElp1 protein, humanReceptors, Tumor Necrosis Factor, Type IITNF protein, humanTNFRSF1B protein, humanTranscriptional Elongation FactorsTumor Necrosis Factor-alphanon-small cell lung cancer (NSCLC)single-nucleotide polymorphismsurvivalTNF receptor (TNFR)tumor necrosis factor (TNF)

Identifiers

PMID30989732
PMCPMC6548610
OpenAlexW2939600874

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.